GSK has not petitioned the Supreme Court over Ellipta products for asthma and chronic obstructive pulmonary disease, which would have been the final route of appeal.
To date, Vectura has received GBP127.6mln from GSK in respect of the US patent litigation which comprises payment for the settlement of damages, associated interest and royalties accrued up to the third quarter, and payment for fourth-quarter ongoing royalties.
As a result, it will pay a special dividend of 19p per share, for a total of GBP113mln.
In a separate announcement, Hikma announced it has resumed the launch of its generic version of GSK’s asthma treatment Advair Diskus in the US following FDA approval.
The pharma company submitted an amendment to its application in January reflecting enhanced packaging controls to meet new industry standards.
Vectura partnered with Hikma for the generic Advair programme last December, which is expected to generate milestones of US$11mln.